In the dose-expansion cohort (crizotinib-resistant ALK-positive; 15 NSCLC; one neuroblastoma), the best overall response was PR in eight patients (50 %) and SD in seven patients (44 %) (Table 5). This evidence concerns the gene ALK and neuroblastoma.